Preferred Label : factor IX;

MeSH definition : Storage-stable blood coagulation factor acting in the intrinsic pathway. Its activated form, IXa, forms a complex with factor VIII and calcium on platelet factor 3 to activate factor X to Xa. Deficiency of factor IX results in HEMOPHILIA B (Christmas Disease).; Storage-stable blood coagulation factor acting in the intrinsic pathway of blood coagulation. Its activated form, IXa, forms a complex with factor VIII and calcium on platelet factor 3 to activate factor X to Xa. Deficiency of factor IX results in HEMOPHILIA B (Christmas Disease).;

MeSH synonym : christmas factor; coagulation factor ix; factor ix fraction; factor ix, coagulation; factor ix complex; autoprothrombin ii; blood coagulation factor ix; plasma thromboplastin component; Factor Nine; Factor 9;

CISMeF synonym : ix complex, factor; ix, coagulation factor; ptc; fraction, factor ix; ix fraction, factor; complex, factor ix;

MeSH CAS label : blood-coagulation factor IX;

Registry Number MeSH : 9001-28-9;

Codes EINECS : 232-594-4;

Is substance : O;

Details


Main resources

You can consult :

Storage-stable blood coagulation factor acting in the intrinsic pathway. Its activated form, IXa, forms a complex with factor VIII and calcium on platelet factor 3 to activate factor X to Xa. Deficiency of factor IX results in HEMOPHILIA B (Christmas Disease).
Storage-stable blood coagulation factor acting in the intrinsic pathway of blood coagulation. Its activated form, IXa, forms a complex with factor VIII and calcium on platelet factor 3 to activate factor X to Xa. Deficiency of factor IX results in HEMOPHILIA B (Christmas Disease).

https://www.has-sante.fr/jcms/p_3218744/fr/idelvion
2020
false
false
false
France
insurance, health, reimbursement
treatment outcome
albutrepenonacog alfa
coagulation factor IX
hemorrhage
hemorrhage
hemophilia B
evaluation of the transparency committee
factor IX
recombinant fusion proteins
serum albumin

---
https://site.geht.org/app/uploads/2019/08/Pouplard-et-al-Dosage-de-lactivité-du-facteur-IX-chez-les-patients-hémophiles-B-substitués-ABC-2019.pdf
2019
false
false
false
France
hemophilia B
Factor IX Activity Measurement
blood chemical analysis
blood coagulation tests
monitoring, physiologic
journal article
hemophilia B
factor IX

---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00378
2018
false
false
false
Canada
French
English
drug information
factor IX
polyethylene glycols
polyethylene glycols
drug evaluation
drug approval
canada
treatment outcome
product surveillance, postmarketing
recombinant proteins
recombinant proteins
adult
child
hemophilia B
hemorrhage
hemorrhage
blood loss, surgical
blood loss, surgical
injections, intravenous
factor IX

---
https://www.has-sante.fr/portail/jcms/c_2825852/fr/refixia
2018
false
false
false
false
France
French
evaluation of the transparency committee
nonacog beta pegol
coagulation factor IX
hemorrhage
hemorrhage
treatment outcome
hemophilia B
injections, intravenous
factor IX
polyethylene glycols
recombinant proteins

---
http://circulaire.legifrance.gouv.fr/index.php?action=afficherCirculaire&hit=1&r=41904
2017
false
false
false
France
French
legislation
factor VIIa
relative
education, nos
hemophilia, nos
mars
factor IX
anti-factor viii
Health Care Category
factor VIII
anti-factor ix

---
Refixia - nonacog beta pegol
https://www.ema.europa.eu/medicines/human/EPAR/Refixia
2017
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
nonacog beta pegol
nonacog beta pegol
coagulation factor IX
treatment outcome
product surveillance, postmarketing
hemorrhage
hemorrhage
hemophilia B
hemophilia B
adult
adolescent
aged
injections, intravenous
drug evaluation, preclinical
factor IX
polyethylene glycols
recombinant proteins
factor IX
polyethylene glycols
recombinant proteins

---
https://www.has-sante.fr/portail/jcms/c_2772241/fr/benefix
2017
false
false
false
France
French
evaluation of the transparency committee
factor IX
recombinant proteins

---
http://www.has-sante.fr/portail/jcms/c_2682486/fr/idelvion-albutrepenonacog-alpha-facteurs-anti-hemophiliques-facteurs-ix
2017
false
false
false
France
French
guidelines for drug use
evaluation of the transparency committee
treatment outcome
factor IX
factor IX
coagulation factor IX
hemophilia B
recombinant fusion proteins
hemorrhage
hemorrhage
orphan drug production
recombinant fusion proteins
adult
adolescent
child
continuity of patient care
injections, intravenous
Albutrepenonacog alfa (substance)

---
http://www.has-sante.fr/portail/jcms/c_2682507/fr/alprolix-eftrenonacog-alpha
2017
false
false
false
France
French
guidelines for drug use
evaluation of the transparency committee
treatment outcome
factor IX
factor IX
coagulation factor IX
hemophilia B
recombinant fusion proteins
hemorrhage
hemorrhage
orphan drug production
recombinant fusion proteins
adult
adolescent
child
continuity of patient care
injections, intravenous
Eftrenonacog alfa (substance)
factor IX Fc fusion protein
factor IX Fc fusion protein
immunoglobulin fc fragments
immunoglobulin fc fragments

---
https://www.ema.europa.eu/medicines/human/EPAR/Idelvion
2016
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
treatment outcome
factor IX
factor IX
hemorrhage
hemorrhage
hemophilia B
Coagulation factor IX variant (substance)
orphan drug production
injections, intravenous
blood coagulation factors
product surveillance, postmarketing
albumins
recombinant proteins
Albutrepenonacog alfa (substance)

---
https://www.ema.europa.eu/medicines/human/EPAR/Alprolix
2016
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
treatment outcome
product surveillance, postmarketing
coagulation factor IX
orphan drug production
hemophilia B
hemorrhage
hemorrhage
injections, intravenous
factor IX Fc fusion protein
factor IX Fc fusion protein
pregnancy
breast feeding
adult
child
drug evaluation, preclinical
Eftrenonacog alfa (substance)
factor IX
immunoglobulin fc fragments
recombinant fusion proteins
factor IX
immunoglobulin fc fragments
recombinant fusion proteins

---
http://www.has-sante.fr/portail/jcms/c_2558862/fr/rixubis
2015
false
false
false
France
French
treatment outcome
coagulation factor IX
factor IX
factor IX
recombinant proteins
hemorrhage
hemorrhage
hemophilia B
injections, intravenous
evaluation of the transparency committee

---
https://www.ema.europa.eu/medicines/human/EPAR/Rixubis
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
coagulation factor IX
factor IX
factor IX
recombinant proteins
drug approval
europe
hemorrhage
hemorrhage
hemophilia B
injections, intravenous
risk management
drug monitoring
product surveillance, postmarketing
drug evaluation, preclinical

---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00172
2014
false
false
false
Canada
French
English
factor IX
factor IX
drug approval
canada
recombinant fusion proteins
recombinant fusion proteins
risk assessment
drug evaluation
adult
child
hemophilia B
hemorrhage
clinical trials as topic
treatment outcome
intraoperative care
summary of product characteristics
factor IX Fc fusion protein
factor IX Fc fusion protein
immunoglobulin fc fragments
immunoglobulin fc fragments

---
http://www.has-sante.fr/portail/jcms/c_1651881/fr/confidex
http://www.has-sante.fr/portail/jcms/c_1651880/fr/confidex-02102013-avis-ct13171
2013
France
French
evaluation of the transparency committee
drug combinations
injections, intravenous
prothrombin
factor IX
factor VII
factor X
coagulation factor ix, ii, vii and x in combination
blood loss, surgical
coagulation protein disorders
blood loss, surgical
protein C
protein S

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=62361438
2012
France
summary of product characteristics
package leaflet
powders
factor IX
humans
injections

---
https://www.ema.europa.eu/medicines/human/EPAR/BeneFIX
2012
false
United Kingdom
French
English
syndication feed
coagulation factor IX
hemophilia B
hemorrhage
hemorrhage
factor IX
factor IX
factor IX
recombinant proteins
package leaflet
summary of product characteristics

---
https://www.ema.europa.eu/medicines/human/EPAR/Nonafact
2010
United Kingdom
English
French
syndication feed
Contraindications, Procedure
hemophilia B
hemorrhage
hemorrhage
factor IX
factor IX
factor IX
factor IX
treatment outcome
drug evaluation
adult
child
adolescent
infusions, intravenous
hemostasis, surgical
coagulation factor IX
drug evaluation
summary of product characteristics
package leaflet
Contraindications, Drug

---
http://www.has-sante.fr/portail/jcms/c_818405/betafact
http://www.has-sante.fr/portail/upload/docs/application/pdf/2009-07/betafact_-_ct-6718.pdf
2009
France
French
evaluation of the transparency committee
factor IX
coagulation factor IX
hemophilia B
hemorrhage
hemorrhage
continuity of patient care
injections
treatment outcome

---
http://www.has-sante.fr/portail/upload/docs/application/pdf/2009-04/kanokad_-_ct-6278.pdf
http://www.has-sante.fr/portail/jcms/c_763774/kanokad
http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-03/kanokad_ct_6278.pdf
2009
France
French
English
factor VII
factor IX
factor X
prothrombin
drug combinations
coagulation factor ix, ii, vii and x in combination
hemorrhage
hemorrhage
hemorrhagic disorders
hemorrhagic disorders
blood loss, surgical
treatment outcome
evaluation of the transparency committee

---
http://www.has-sante.fr/portail/jcms/c_816557/confidex-complexe-prothrombique-humain-ppsb-facteurs-de-la-coagulation
http://www.has-sante.fr/portail/jcms/c_818184/synthese-d-avis-confidex-ct-6478
2009
false
France
French
drug combinations
prothrombin
factor VII
blood loss, surgical
factor IX
factor X
blood loss, surgical
coagulation protein disorders
blood coagulation factors
prothrombin complex concentrates
coagulation factor ix, ii, vii and x in combination
blood coagulation factors
protein S
protein C
guidelines for drug use
evaluation of the transparency committee

---
http://www.has-sante.fr/portail/jcms/c_697304/octafix
http://www.has-sante.fr/portail/upload/docs/application/pdf/2008-09/octafix_ct-5518.pdf
2008
France
French
factor IX
child
injections
coagulation factor IX
treatment outcome
hemophilia B
hemorrhage
hemorrhage
evaluation of the transparency committee

---
Nous contacter.
11/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.